Anti-Parasitic Compounds from Streptomyces sp. Strains Isolated from Mediterranean Sponges

Marine Drugs

Sheila Marie Pimentel-Elardo²  Svitlana Kozytska¹  Tim S. Bugni³  Chris M. Ireland³  Heidrun Moll¹ 

[1] Research Center for Infectious Diseases, Josef-Schneider-Straße 2, 97080 Würzburg, Germany;Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs Platz 3, 97082 Würzburg, Germany;Department of Medicinal Chemistry, University of Utah, Salt Lake City, 84112 Utah, USA

关键词: marine sponges;    Streptomyces;    valinomycin;    staurosporine;    butenolide;    anti-parasitic;   

DOI  :  10.3390/md8020373

来源: mdpi

【 摘 要 】

Actinomycetes are prolific producers of pharmacologically important compounds accounting for about 70% of the naturally derived antibiotics that are currently in clinical use. In this study, we report on the isolation of Streptomyces sp. strains from Mediterranean sponges, on their secondary metabolite production and on their screening for anti-infective activities. Bioassay-guided isolation and purification yielded three previously known compounds namely, cyclic depsipeptide valinomycin, indolocarbazole alkaloid staurosporine and butenolide. This is the first report of the isolation of valinomycin from a marine source. These compounds exhibited novel anti-parasitic activities specifically against Leishmania major (valinomycin IC₅₀ < 0.11 μM; staurosporine IC₅₀ 5.30 μM) and Trypanosoma brucei brucei (valinomycin IC₅₀ 0.0032 μM; staurosporine IC₅₀ 0.022 μM; butenolide IC₅₀ 31.77 μM). These results underscore the potential of marine actinomycetes to produce bioactive compounds as well as the re-evaluation of previously known compounds for novel anti-infective activities.

【 授权许可】

CC BY   
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland